Today marks a major development as the Phase 2b study of amlitelimab, known as STREAM-AD, has yielded promising results in adults suffering from moderate to severe atopic dermatitis that could not be adequately controlled through topical medications. The study compared the efficacy of four subcutaneous doses of amlitelimab to a placebo, with remarkable results in average Eczema Area and Severity Index (EASI) scores, key secondary outcomes, and biomarker results that suggest a beneficial effect on both type 2 and non-type 2 pathways.
Remarkably, the treatment was found to be safe and well-tolerated without any new safety issues. This exciting new breakthrough could finally provide much-needed relief for those struggling with this challenging condition.
Naimish Patel, M.D.
We are excited about the progress we are making in the treatment of atopic dermatitis and are passionate about providing new options to those in need. The Phase 2b study results of amlitelimab have strengthened our belief that targeting OX40-Ligand could be the first-in-class solution for treating type 2 and non-type 2 inflammation.
We are committed to advancing to the Phase 3 clinical development program, making further strides in our Immunology pipeline and providing first or best-in-class treatments for individuals living with atopic dermatitis and other chronic inflammatory diseases.
Amlitelimab is an exciting advancement in treating immune-mediated diseases and inflammatory disorders. This revolutionary fully human non-depleting monoclonal antibody has the potential to restore the balance between pro-inflammatory and regulatory T cells by effectively binding to OX40-Ligand, a key immune regulator.
It is currently being studied for its potential to improve symptoms of moderate-to-severe atopic dermatitis and asthma. Results from this initial trial are yet to be released, and amlitelimab awaits regulatory approval for its efficacy and safety. Watch this space for future scientific developments!
AboutSTREAM-AD
A Phase 2b study, STREAM-AD, recently investigated the use of amlitelimab in adult patients with moderate-to-severe atopic dermatitis. The study was a double-blind, placebo-controlled trial with the primary endpoint being the percentage change in EASI from baseline at 16 weeks. Secondary endpoint outcomes included percentage of patients with at least a 75% reduction in EASI, a response of IGA 0 (clear) or 1 (almost clear), and an improvement (reduction) of weekly average of pruritus NRS from baseline at 16 and 24 weeks. The study found amlitelimab to be a promising treatment option for those whose disease was inadequately controlled by topical therapies or where such therapies were not advisable.
The study enrolled 390 people in Australia, Bulgaria, Canada, Czechia, Germany, Hungary, Japan, Poland, Spain, Taiwan, the United Kingdom and the United States.
About Sanofi
We are a pioneering healthcare company on a mission to transform medicine, one miracle of science at a time! We strive to bring life-changing solutions and life-saving vaccine protection to millions of people across the globe, all with sustainability and social responsibility at the heart of everything we do. Our dedicated teams in over 100 countries work tirelessly together to make the impossible, possible.